Procter & Gamble Health Ltd. (PGHL) AI Stock Analysis

• Market Cap: ₹90.51B
• Dividend Yield: 3.28%
• Average Volume (3M): 310.00
• Price to Earnings (P/E): 29.2
• Beta (1Y): 0.57
• Revenue Growth: 3.01%
• EPS Growth: 22.98%
• Country: IN
• Employees: 1,336
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 53.34
• Shares Outstanding: 16,599,382
• 10 Day Avg. Volume: 340
• 30 Day Avg. Volume: 310
• PEG Ratio: 1.37
• Price to Book (P/B): 15.96
• Price to Sales (P/S): 7.03
• P/FCF Ratio: 51.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: ₹6,857.00 ▲(19.22% Upside)

Procter & Gamble Health Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet, contributing significantly to the overall score. The technical analysis indicates mixed signals with short-term bearish momentum but a long-term bullish trend. The valuation is slightly high, reflecting growth expectations, but the attractive dividend yield provides a buffer. The absence of earnings call data and corporate events does not impact the score.

Positive Factors

Financial Stability

A low debt-to-equity ratio indicates minimal leverage and financial risk, ensuring the company can sustain operations and invest in growth without excessive debt burden.

Profitability

Consistent profitability and margin growth highlight efficient operations and pricing power, supporting long-term financial health and shareholder returns.

Cash Generation

Efficient cash generation relative to net income indicates robust operational performance, providing funds for reinvestment and shareholder distributions.

Negative Factors

Cost Management

Declining gross profit margins indicate rising costs, which could pressure profitability if not managed effectively, impacting long-term financial performance.

Operational Efficiency

Lower operational cash flow efficiency suggests potential inefficiencies in converting income to cash, which could affect liquidity and investment capacity.

Growth Challenges

While current growth is strong, sustaining high growth rates may be challenging in a competitive market, requiring continuous innovation and market expansion.

Procter & Gamble Health Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas brands. Procter & Gamble Health Limited also exports its pharmaceutical products to Sri Lanka, Nepal, Myanmar, and Maldives. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.

How the Company Makes Money

PGHL generates revenue primarily through the sale of its health-related products, which are marketed under well-known brands. The company utilizes a multi-channel distribution strategy, including retail partnerships, e-commerce platforms, and direct-to-consumer sales. Key revenue streams include prescription and over-the-counter medications, vitamins and supplements, and oral hygiene products. Additionally, PGHL benefits from strategic partnerships with healthcare providers and organizations that enhance product visibility and consumer trust. The company's strong brand equity and continued investment in research and development also contribute significantly to its earnings by ensuring a steady pipeline of innovative health solutions.

Procter & Gamble Health Ltd. Financial Statement Overview

Summary

Procter & Gamble Health Ltd. exhibits a strong financial position across all verticals. The income statement reflects robust profitability and growth, while the balance sheet indicates excellent financial stability with low leverage. The cash flow statement is positive, with strong cash generation capabilities. The company is well-positioned for future growth, though there is room for improvement in cost management and operational efficiency.

Income Statement

Procter & Gamble Health Ltd. demonstrates strong profitability with a consistent increase in net profit margin and EBIT margin over the years. The company has shown a healthy revenue growth rate of 7.42% in the most recent year, indicating robust sales performance. However, the gross profit margin has declined slightly, suggesting increased cost pressures. Overall, the income statement reflects a solid financial performance with room for improvement in cost management.

Balance Sheet

The balance sheet of Procter & Gamble Health Ltd. is very strong, characterized by a low debt-to-equity ratio of 0.014, indicating minimal leverage and financial risk. The return on equity is impressive at 58.21%, showcasing efficient use of shareholder funds to generate profits. The equity ratio is healthy, reflecting a strong capital structure. Overall, the balance sheet is robust, with excellent financial stability and low risk.

Cash Flow

The cash flow statement shows a positive trajectory with strong free cash flow to net income ratio of 0.95, indicating efficient cash generation relative to net income. The operating cash flow to net income ratio is slightly lower at 0.82, suggesting room for improvement in operational efficiency. The free cash flow growth rate is exceptionally high, but this is due to a low base effect. Overall, the cash flow position is solid, with potential for enhanced operational cash flow management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	32.74B	12.18B	11.51B	12.30B	11.14B	10.09B
Gross Profit	23.61B	8.69B	8.09B	8.46B	7.61B	6.84B
EBITDA	9.51B	3.62B	3.03B	3.19B	2.65B	2.42B
Net Income	7.01B	2.51B	2.01B	2.29B	1.93B	1.77B
Balance Sheet
Total Assets	0.00	7.94B	7.94B	11.01B	8.94B	9.86B
Cash, Cash Equivalents and Short-Term Investments	1.89B	1.89B	2.44B	4.53B	3.19B	4.64B
Total Debt	0.00	76.20M	95.60M	120.00M	28.30M	76.10M
Total Liabilities	-5.37B	2.57B	2.56B	3.50B	2.77B	2.82B
Stockholders Equity	5.37B	5.37B	5.38B	7.51B	6.16B	7.04B
Cash Flow
Free Cash Flow	919.80M	1.67B	2.07B	1.94B	1.32B	1.95B
Operating Cash Flow	984.40M	1.76B	2.28B	2.36B	1.70B	2.47B
Investing Cash Flow	-1.00M	24.40M	-68.70M	-215.00M	-255.40M	-322.70M
Financing Cash Flow	-2.67B	-2.35B	-4.18B	-984.70M	-2.89B	-3.87B

Procter & Gamble Health Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5751.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Negative. The current price of 5751.7 is above the 20-day moving average (MA) of 5669.35, below the 50-day MA of 5771.50, and below the 200-day MA of 5797.56, indicating a bearish trend. The MACD of -43.10 indicates Positive momentum. The RSI at 33.02 is Neutral, neither overbought nor oversold. The STOCH value of 16.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PGHL.

Procter & Gamble Health Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGHL	73 Outperform	₹90.51B	29.24	―	3.28%	3.01%	22.98%
SYMPHONY	70 Outperform	₹62.17B	47.78	―	1.43%	-19.72%	-44.03%
ZYDUSWELL	66 Neutral	₹140.37B	55.26	―	0.28%	14.55%	-20.61%
SURYAROSNI	63 Neutral	₹58.42B	17.62	―	2.03%	0.31%	1.98%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
JYOTHYLAB	61 Neutral	₹95.55B	27.45	―	1.24%	1.62%	-7.32%
EVEREADY	55 Neutral	₹23.53B	51.91	―	0.46%	7.37%	-39.19%